A Phase 1/2 interventional study of RMC-6236 and mFOLFOX6 regimen in Colorectal Cancer, CRC and Pancreatic Ductal Adenocarcinoma, sponsored by Revolution Medicines, Inc.. Recruiting at 32 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-22.
Sponsored by Revolution Medicines, Inc. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 187 studies testing cetuximab in Colorectal Neoplasms — 35 open to participants now, 43 under way, 7 of them phase 3. Cetuximab · Colorectal Neoplasms.
Among the 187 studies testing cetuximab in Colorectal Neoplasms, this one is the 7th largest by planned enrollment of the 185 interventional ones that give a count, is one of 17 that started in 2024, is one of 20 in phase 1/2, reaches primary completion later than 29 of the 42 other live ones, and was the 170th registered.
6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →35 of the 187 studies testing cetuximab in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Haisco Pharmaceutical Group Co., Ltd. · Sites in China
Ages 18+
Verastem, Inc. · Sites in United States, Australia
Ages 18+
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sites in China
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Cetuximab: first FDA approval 2004 (ERBITUX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
187 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 39 · Phase 2 131 · Phase 3 33 · Phase 4 4
First in 1999; this study’s year is marked. 17 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,130 is above the median of 76 across 4,805 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 60 across the 185 interventional studies. Of the 108 that completed or were terminated, 29 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 187 have an industry lead sponsor. The 10 most frequent:
Revolution Medicines, Inc. is the lead sponsor of 20 studies on the registry; 13 are open to participants now.
Revolution Medicines, Inc. has 8 studies filed under Colorectal Neoplasms — fewer than ten, so there is no comparison to draw.
6 of the studies testing cetuximab in Colorectal Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06226857Phase 3City Clinical Oncology Hospital No 1Other Oncogene Mutations for Anti-EGFR Efficacy in Patients With Left-sided RAS-wild Type Metastatic Colorectal Cancer | 2026-12-31 |
| NCT06321081Beijing HospitalICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC | 2026-12-30 |
| NCT05706779Federation Francophone de Cancerologie DigestiveEncorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum Cancer | 2026-12-30 |
| NCT06411600Vall d'Hebron Institute of OncologyCombination Therapy for BRAF-V600E Metastatic CRCm | 2027-05-01 |
| NCT07659795Verastem, Inc.A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer | 2027-06 |
Add all 6 to your calendar (.ics) → With an account.
Among the 187 studies testing cetuximab in Colorectal Neoplasms, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents.
The current subprotocols include the following:
Subprotocol A: RMC-6236 + 5-fluorouracil-based regimens
Subprotocol B: RMC-6236 + cetuximab with or without mFOLFOX6
Subprotocol C: RMC-6236 + gemcitabine + nab-paclitaxel
Subprotocol D: RMC-9805 with or without RMC-6236 + 5-fluorouracil-based regimens
Subprotocol E: RMC-9805 with or without RMC-6236 + cetuximab with or without mFOLFOX6
Subprotocol F: RMC-9805 with or without RMC-6236 + gemcitabine + nab-paclitaxel
Subprotocol G: RMC-9805 + cetuximab + FOLFIRI
The platform study design allows combinations of RAS(ON) inhibitors with other anticancer agents to be evaluated in patients with RAS-mutated solid tumors with a focus on GI cancers.
This is an open-label platform study to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard of Care (SOC) or with novel agents, and to define the Recommended Phase 2 Dose and Schedule (RP2DS). Enrollment of patients with RAS mutations will be specified in each subprotocol.
Subprotocol A is an open-label, multicenter study of RMC-6236 in combination with 5-fluorouracil-based regimens in patients with treatment-naïve unresectable or metastatic colorectal cancer or treatment-naïve metastatic pancreatic ductal adenocarcinoma. Subprotocol B is an open-label, multicenter study of RMC-6236 in combination with cetuximab with or without mFOLFOX6 in patients with unresectable or metastatic colorectal cancer or patients with previously treated or treatment-naïve metastatic pancreatic ductal adenocarcinoma. Subprotocol C is an open-label, multicenter study of RMC-6236 in combination with gemcitabine and nab-paclitaxel in patients with treatment-naïve metastatic pancreatic ductal adenocarcinoma. Subprotocol D is an open-label, multicenter study of RMC-9805 with or without RMC-6236 in combination with 5-fluorouracil-based regimens in patients with RAS G12D-mutant unresectable or metastatic colorectal cancer or metastatic pancreatic ductal adenocarcinoma. Subprotocol E is an open-label, multicenter study of RMC-9805 with or without RMC-6236 in combination with cetuximab-based therapies with or without mFOLFOX6 in patients with RAS G12D-mutant unresectable or metastatic colorectal cancer or metastatic pancreatic ductal adenocarcinoma. Subprotocol F is an open-label, multicenter study of RMC-9805 with or without RMC-6236 in combination with gemcitabine and nab-paclitaxel in patients with RAS G12D-mutant metastatic pancreatic ductal adenocarcinoma. Subprotocol G is an open-label, multicenter study of RMC-9805 with cetuximab and FOLFIRI in patients with previously treated, RAS G12D-mutated metastatic colorectal cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
All Patients (unless otherwise noted):
Exclusion Criteria:
All Patients:
Other inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RMC-6236 (QD) and bevacizumab with 5-fluorouracil-based regimens
Drug: RMC-6236 · Drug: mFOLFOX6 regimen · Drug: bevacizumab · Drug: mFOLFIRINOX regimen
RMC-6236 (QD) and cetuximab with or without mFOLFOX6
Drug: RMC-6236 · Drug: mFOLFOX6 regimen · Drug: cetuximab
RMC-6236 (QD) and gemcitabine with nab-paclitaxel
Drug: RMC-6236 · Drug: gemcitabine · Drug: nab-paclitaxel
RMC-9805 (QD or BID) with or without RMC-6236 (QD), and bevacizumab with 5-fluorouracil- based regimens
Drug: RMC-6236 · Drug: mFOLFOX6 regimen · Drug: bevacizumab · Drug: mFOLFIRINOX regimen · Drug: RMC-9805
RMC-9805 (QD or BID) with or without RMC-6236 (QD), and cetuximab with or without mFOLFOX6
Drug: RMC-6236 · Drug: mFOLFOX6 regimen · Drug: cetuximab · Drug: RMC-9805
RMC-9805 (QD or BID) with or without RMC-6236 (QD), and gemcitabine with nab-paclitaxel
Drug: RMC-6236 · Drug: gemcitabine · Drug: nab-paclitaxel · Drug: RMC-9805
RMC-9805 (QD) and cetuximab with FOLFIRI
Drug: cetuximab · Drug: RMC-9805 · Drug: FOLFIRI regimen
Oral tablet
IV infusion
IV infusion
IV infusion
IV infusion
IV infusion
IV infusion
Oral Tablet
IV infusion
Adverse events (Subprotocols A-F)
Evaluate the safety and tolerability in the study population characterized by incidence, abnormal laboratory assessments, severity, and seriousness of adverse events in relation to the study treatment.
Time frame: Up to 3 years
Dose limiting toxicities (Subprotocols A-F)
Number of participants with dose limiting toxicities
Time frame: 28 days
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) as assessed by Blinded Independent Central Review (BICR)(Subprotocol G)
Time frame: Up to 3 years
Pharmacokinetics of RMC-6236 (Subprotocols A-F)
Blood concentration of RMC-6236 over time
Time frame: 21 weeks
Pharmacokinetics of RMC-9805 (Subprotocols D-G)
Blood concentration of RMC-9805 over time
Time frame: 21 weeks
ORR assessed by Investigator (Subprotocols A-G)
Overall Response Rate per RECIST v1.1
Time frame: Up to 3 years
DOR (Subprotocols A-G)
Duration of Response per RECIST v1.1
Time frame: Up to 3 years
DCR (Subprotocols A-G)
Incidence of Response per RECIST v1.1
Time frame: Up to 3 years
TTR (Subprotocols A-G)
Time to Response per RECIST v1.1
Time frame: Up to 3 years
PFS (Subprotocols A-G)
Progression Free Survival per RECIST v1.1
Time frame: Up to 3 years
PFS Rate at 6 and 12 Months (Subprotocol G)
Time frame: Up to 3 years
OS (Subprotocols A-F)
Overall Survival
Time frame: Up to 3 years
Overall Survival Rate at 12 Months (Subprotocol G)
Time frame: Up to 3 years
Number of Participants with Adverse Events (Subprotocol G)
Time frame: Up to 3 years
Started May 2024 (actual). Primary completion is estimated for Sep 2028, 52 months after the start.
Of 158 industry-sponsored phase 1/2 interventional studies under Colorectal Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 82. This study's planned 52 months is below that.
Counting every sponsor, half of 260 studies reached it within 59 months; a quarter within 36 and three quarters within 87.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Daraxonrasib · Cetuximab · Zoldonrasib